Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Lili Du, W. Fraser Symmans, Lamorna Brown Swigart et al.|Annals of Oncology|2021

Cited by 46